Latest Blogs

USP 1033: A Validation Example

In the previous parts of our series covering the latest draft version of USP <1033>, we examined the goals of a bioassay validation study and the basics of accuracy... read more →

22nd April 2026
All Blogs, Bioassay

Bayesian Sample Size Calculations for Clinical Trials

A key decision in the planning of a clinical trial is that of the sample size. As we’ve discussed previously, the number of participants in a trial is key... read more →

11th March 2026
All Blogs, Clinical

USP 1033: Bioassay Validation Acceptance Criteria

In the first part of our series examining USP <1033> in depth, we discussed the goals of bioassay validation – specifically, to demonstrate that an assay is suitable for... read more →

25th February 2026
All Blogs, Bioassay

Can you Validate a Spreadsheet? Using Bespoke Software Tools for GxP Analysis

During the early development of many therapeutic products, analytical and data management processes are often created quickly and pragmatically. Excel spreadsheets, macros, and bespoke code are widely used because... read more →

11th February 2026
All Blogs, Bioassay

USP <1033>: The Goals of Bioassay Validation

One can think of the life of a bioassay in two main acts. First comes the design and development of the assay, where the assay method is conceptualised, refined,... read more →

28th January 2026
All Blogs, Bioassay

The Challenges of Correlation: SPC for Bioassay Data

One common use for bioassays is to test manufactured biologic products before they are released to the wider consumer market. While all bioassays used for this purpose will have... read more →

14th January 2026
All Blogs, Bioassay

Biosimilars: Are Comparative Efficacy Studies Required?

It is far from a controversial statement that biologic therapeutics – such as monoclonal antibody and recombinant protein therapies – are complex and expensive to develop. As one might... read more →

10th December 2025
All Blogs, Bioassay

Interval Training: Confidence, Prediction, Tolerance

Statistics is hard, words are harder. So often when working through the statistics behind a bioassay, the correct path is obscured behind a word salad of jargon placed seemingly... read more →

26th November 2025
All Blogs, Bioassay

Is Outlier Misidentification a Problem in Bioassay?

So far in our series examining approaches to outlier management in bioassay, we’ve discussed the various perspectives on outliers held by stakeholders in the bioassay lifecycle and the problems... read more →

12th November 2025
All Blogs, Bioassay

Identifying Outliers: Grubbs’ Test and Studentised Residuals

Previously, we examined the reasons why one might consider attempting to identify and remove outliers from bioassay data. From a scientific perspective, omitting any collected data is never ideal,... read more →

29th October 2025
All Blogs, Bioassay

Outlier Detection Methods for Bioassay: What is an Outlier?

Outliers are among the topics which stimulate the most vigorous debate among the bioassay community. When a datapoint falls outside of the usual range observed for that metric, it... read more →

15th October 2025
All Blogs, Bioassay

Driving Below the LOQ: Statistical Analysis of Unquantifiable Data

In many fields of science, researchers often face the challenge of measuring extremely small quantities. The life sciences are no exception, with experiments regularly requiring accurate and precise detections... read more →

1st October 2025
All Blogs, Bioassay

Challenges of Clinical Trials for Vaccines: Sample Sizes

To perform any experiment, it is vital to ensure that enough data is collected. Too little data can not only mean imprecise results, but also makes distinguishing between reality... read more →

17th September 2025
All Blogs, Clinical, Vaccines

Vaccine Batch Release: Bridging In Vivo to In Vitro

In In Vitro vs In Vivo Potency Assays: Modern Vaccine Batch Release, we examined the pros and cons of two methods of testing vaccine potency: in vivo assays, which... read more →

3rd September 2025
All Blogs, Bioassay, Vaccines

Correlates of Protection: Vaccine Development under FDA Animal Rule

One key challenge when developing vaccines for human use is that it is often infeasible or unethical to assess the efficacy of the candidate vaccine directly in humans. As... read more →

20th August 2025
All Blogs, Clinical, Vaccines

Defining a Statistical Analysis for Bioassay: Response Modelling

The previous blogs in our collaboration with the team at RoukenBio – the Immunology CRO redefined – have focused predominantly on the biological aspects of bioassay development. Including aspects... read more →

6th August 2025
All Blogs, Bioassay

Countdown to Immunity: Testing Vaccine Onset of Protection

When we discuss the performance of a vaccine, properties such as its immunogenicity, adverse event frequency, and any correlates of protection are usually among the first to be mentioned.... read more →

23rd July 2025
All Blogs, Clinical, Vaccines

Understanding Preclinical Vaccine Safety: Regulatory Guidelines Explained

Vaccines are one of the few medical interventions which are regularly undertaken by healthy individuals. As a result, the bar for ensuring the safety of a vaccine is extremely... read more →

9th July 2025
All Blogs, Clinical, Vaccines

From Equivalence to Alarm: Bioassay Limits Explained

Bioassays are typically used to measure the properties of a manufactured product to ensure that it is of sufficient quality for use by patients. Inherent in this process is... read more →

25th June 2025
All Blogs, Bioassay

Preclinical Research: The Kingmaker of Vaccine Development

Vaccine development often only hits the headlines when there’s a breakthrough clinical trial or final approval. Behind every successful vaccine, however, is a lesser-known stage of research that quietly... read more →

11th June 2025
All Blogs, Clinical, Vaccines

Building your Bioassay: Cell Substrates (with RoukenBio)

In the next part of our ongoing collaboration, the team at RoukenBio take a look at a key decision point early in the lifecycle of a potency assay: what... read more →

21st May 2025
All Blogs, Bioassay, Building your Bioassay

Choosing a Path: Natural History Studies for Vaccine Development

The earliest stages of the development of any vaccine involve laying out the roadmap for its design and testing. A vast network of interlinked paths from a new idea... read more →

14th May 2025
All Blogs, Clinical, Vaccines

Testing Diagnostics: Qualifying In Vitro Devices

If you’ve ever taken a rapid test for COVID-19, then you’ve used an in vitro diagnostic device (IVD). At the start of the pandemic, the only reliable method for... read more →

30th April 2025
All Blogs, Clinical, Devices

Assay Transfers: A Guide to USP <1224>

A bioassay supporting a commercial product often has a lifespan of several years or even decades. Over that time, it is often necessary that the assay be performed in... read more →

16th April 2025
All Blogs, Bioassay

A Statistical Understanding of Polyclonality in Monoclonal Antibody Production

Therapies based on monoclonal antibodies (mAbs) are among the most powerful medical technologies to have been developed in recent years. From treatments designed to attack cancer cells and prevent... read more →

2nd April 2025
All Blogs, Bioassay

Reference Bridging for Bioassays: Techniques and Best Practice

Management of the reference standard over the life of a product is critical to ensuring consistent production of material. We always want to be able to draw a link... read more →

19th March 2025
All Blogs, Bioassay

Design of Experiments for Bioassay Optimisation (with RoukenBio)

So, you’re confident that you’ve got a feasible assay with a well-defined dose-response curve. But bioassays, as we all know, are fickle. The observed responses are sensitive to many... read more →

19th February 2025
All Blogs, Bioassay, Building your Bioassay

Statistical Sample Size Calculations for Clinical Trials

When scientific a study is evaluated, the sample size is often among the first issues brought up. Whether it’s the number of participants in a study, the number of... read more →

7th January 2025
All Blogs, Clinical

In Vitro vs In Vivo Potency Assays: Modern Vaccine Batch Release

Vaccines are among the most important technological developments in human history. From the earliest attempts to prevent smallpox by variolation to modern mRNA vaccines built without a virus needing... read more →

12th December 2024
All Blogs, Bioassay, Vaccines

Examining the Three-Parameter Logistic (3PL) curve for Bioassay Modelling

One of the most frequent topics of discussion on this blog has been the correct and optimal utilisation of different classes of statistical models with bioassay data. Most common... read more →

31st October 2024
All Blogs, Bioassay

Using Statistical Process Control (SPC) for Bioassays

Bioassays serve as a method of testing a product: does the latest batch of our biologic have an acceptable potency? To do this effectively, we need to ensure that... read more →

1st October 2024
All Blogs, Bioassay

Making the most of your bioassay control wells

The control: a vital part of any scientific experiment. The only way to establish causality between the dependent and independent variables in an experiment is by comparison with a... read more →

17th September 2024
All Blogs, Bioassay

Bootstrapping in the Biosciences: A Guide

The idiom “to pull oneself up by their boostraps” originated in the late 19th century. At first, it implied impossibility , but has since shifted to mean advances achieved through... read more →

29th August 2024
All Blogs, Clinical

What is the 5PL Formula?

In bioassay analyses, there are three statistical models that are commonly fit to dose-response data: the linear model, the 4PL model, and the 5PL model. We’ve examined the properties... read more →

6th August 2024
All Blogs, Bioassay

ELISA Bioanalysis: Key Advantages of the BY Method

Enzyme-Linked Immunosorbent Assays (ELISA) are a key tool for determining concentrations, forming a key component of many fields in the life sciences. From testing food products for allergens to... read more →

27th June 2024
All Blogs, Bioassay

Optimising Suitability Criteria for Bioassays

When running a bioassay, we face a constant battle between two competing requirements. The assay must be able to detect when something has gone wrong with the experiment or... read more →

4th June 2024
All Blogs, Bioassay

Understanding GLP Carcinogenicity Studies: OECD 451 & 116

The Organisation for Economic Co-operation and Development (OECD) is an inter-governmental organisation which aims to facilitate global trade and economic development. A key area is the development of global... read more →

23rd May 2024
All Blogs, Ecotox

Potency Assays for Cell and Gene Therapy: Statistical Challenges

At the forefront of medical development lies the world of cell and gene therapy. Unlike traditional, small molecule therapeutics, treatments based on biologics can treat, cure, or even prevent... read more →

14th May 2024
All Blogs, Bioassay

What are Bayesian Statistics, and When Should I Use Them?

Statistics is divided between two camps: the frequentists and the Bayesians. The latter of these has begun to attract more popular attention in recent years with the rise of... read more →

3rd May 2024
All Blogs, Clinical

Why Weight? Response Weighting for Bioassays

A concept we’ve discussed several times over the years is that of homogeneity of variance. We highlight it so regularly as it’s among the most critical properties that relative... read more →

23rd April 2024
All Blogs, Bioassay

Compartmental PK Models: PK/PD Analysis II

In previous blogs, we’ve examined the statistics behind Non-Compartmental PK/PD analysis. The existence of the Non-Compartmental Analysis (NCA) implies the existence of compartmental analysis, and, indeed, it is among... read more →

4th March 2024
All Blogs, Clinical

Bioequivalence: Interpreting the FDA Guidances for a Nasal Spray

In our blog introducing bioequivalence, we described how studies establishing bioequivalence can be a way to avoid expensive clinical trials without compromising on the safety or efficacy of a... read more →

1st March 2024
All Blogs, Clinical

Bioassay Optimisation: Save time, Save Money

Bioassays can be expensive, both in terms of time and money. It is, therefore, sensible to consider bioassay optimisation: ways to design assays which minimise resource use while maximising... read more →

17th January 2024
All Blogs, Bioassay

How to Build a Confidence Interval

In parts 1 & 2 of our series on the confidence interval, we have covered some of the basic statistical concepts – means, standard deviations, and distributions –... read more →

19th December 2023
All Blogs, Bioassay

Statistical Software Validation: A Risk-Based Approach

Validation of statistical software is required for use in regulatory work. Many auditors expect to see the traditional IQ, OQ, PQ approach applied to the base system (SAS, R,... read more →

1st December 2023
All Blogs, Bioassay, Clinical

Should I Average My Pseudo-replicates?

A common discussion we at Quantics have with our clients surrounds the issue of pseudo-replicates. It’s an area of tension between scientist and statistician – pseudo-replicates reduce the cost... read more →

9th November 2023
All Blogs, Bioassay

USP 1033: Top 3 Highlights from New Draft Guidances

The United States Pharmacopeia (USP) guidance on biological assay validation, General Chapter <1033>, will soon be updated. In the leadup to the publication of the new guidance,... read more →

20th September 2023
All Blogs, Bioassay

The Confidence Interval II: Standard Error & Central Limit Theorem

In part 1 of our series covering the confidence interval, we examined some of the basic statistical concepts associated with a bioassay. In particular, we saw that a... read more →

11th September 2023
All Blogs, Bioassay

What is Bioequivalence?

One of the greatest challenges in the development of new drugs and therapeutics is that it’s just plain expensive. The average spend on a drug which passes clinical trial... read more →

22nd August 2023
All Blogs, Bioassay, Clinical

Un-confusing the Confidence Interval

A crucial acknowledgement of the scientific method is that no measurement will ever be perfect: results will always have associated variability, no matter how sophisticated the methodology used. Bioassay... read more →

8th August 2023
All Blogs, Bioassay

Non-Compartmental Analysis (NCA): The Basics of PK/PD Statistics, Part 1

Crucial in understanding the safety and efficacy of a drug are how it percolates through the body, or pharmacokinetics (PK), and how the body responds to its presence,... read more →

5th July 2023
All Blogs, Clinical

AI, Machine Learning and Medical Regulators

Unless you’ve been hiding under a rock for the past few months (and, honestly, who could blame you), you will have interacted with artificial intelligence (AI) in some form.... read more →

17th May 2023
All Blogs, Clinical, Devices

What is Parallelism in Bioassay?

In the most basic sense, relative potency bioassays consist of a comparison of the behaviour of a reference standard to that of a test sample. That process is not... read more →

5th April 2023
All Blogs, Bioassay

Randomisation for Clinical Trials: A Guide

When James Lind (of Edinburgh, no less) first tested vitamin C as a cure for scurvy in 1747, he happened upon an experiment design which has persisted to this... read more →

22nd March 2023
All Blogs, Clinical, Devices

What is the 4PL Formula?

Picture the scene. You’re busily developing your assay and its data fits your chosen 4PL model beautifully. You’re just about to move onto validation—everything’s going so well!—but, out... read more →

15th March 2023
All Blogs, Bioassay

Understanding Absolute and Relative Potency Assays for Optimal Results

Relative. Thanks for reading…But wait a moment! Have you ever stopped to ask why relative potency (RP) assays are the most common potency assay? Perhaps there are cases where... read more →

8th February 2023
All Blogs, Bioassay

Population PK (PopPK): The What, The How, and The Why

Population Pharmacokinetics (PopPK) is the gold standard method of understanding drug safety and efficacy, particularly as it provides a unique insight into the variation of drug behaviour from person... read more →

31st January 2023
All Blogs, Clinical, HTA

Understanding Cut-Point Analysis for ADA Assays

What are the most important properties of a new drug? Ultimately, we want to ensure that any new therapy treats what it is designed to treat—that it’s effective—and that... read more →

20th December 2022
All Blogs, Bioassay

R² II: What should you use to measure Goodness-of-Fit?

In the first part of this series, we investigated the use of the coefficient of determination—R2—to measure goodness-of-fit. Specifically, we showed that it is an inadequate tool: a... read more →

30th November 2022
All Blogs, Bioassay

Coefficient of Variation (CV) – a suitability criterion?

One of the most important concepts in bioassay is that of replication. Test samples are regularly replicated 2 or 3 times. Multiple response measurements at each dose will, in... read more →

26th October 2022
All Blogs, Bioassay

R We Nearly Squared Yet? Why R² is a Poor Metric for Goodness-of-Fit

One of the most important metrics when analysing bioassay data is goodness-of-fit — how well does a dataset fit a chosen model? In development, this question can... read more →

6th October 2022
All Blogs, Bioassay

Software: The BEBPA Sessions

This is the third blog responding to the software discussions at the BEBPA US 2022 conference. Blog One: formulae can be found here and Blog Two: Algorithms used can... read more →

14th June 2022
All Blogs, Bioassay, Bioassay DE

Fitting Algorithms: The BEBPA Sessions

This is the second mini blog responding to the software discussions at the BEBPA US 2022 conference. Blog One: Formulae - can be found here. The key driver for... read more →

17th May 2022
All Blogs, Bioassay, Bioassay DE

Statistical Model Formulae: The BEBPA Sessions

Myself, and my colleague Brooke, attended the BEBPA US virtual meeting last week and reported back on the presentation and round table discussions on relative potency software, including some... read more →

14th April 2022
All Blogs, Bioassay

Choosing the best Parallel Line Analysis (PLA) software for your lab

Choosing the right Parallel Line Analysis (PLA) software for your lab is not an easy task. Whilst there are several packages available, and most can perform an adequate standard... read more →

17th March 2022
All Blogs, Bioassay

Multiplicity in a Clinical Trial: Why is it Important?

This blog introduces the concept of multiplicity, why it is important and offers some techniques for dealing with the issue. When planning a clinical study, lots of thought is... read more →

18th January 2022
All Blogs, Clinical

Zero Dose Control – An extra data point for free!

At the recent BEBPA meeting, in response to the question: 'If you have a zero dose control on your plate do you include it in your 4PL model?' 78%... read more →

29th October 2021
All Blogs, Bioassay

Accuracy, Precision and Bias

Accuracy and Precision are properties of an experiment which are often conflated – not least because they are often synonymous in everyday conversation. In science, however, they have separate,... read more →

9th August 2021
All Blogs, Bioassay

ML-NMR: the Future of Population Adjustment?

This is the third blog in our trilogy on techniques for population adjustment in network meta-analysis (NMA). Here we will focus on an approach called Multi-Level Network Meta-Regression (ML-NMR),... read more →

14th April 2021
All Blogs, HTA

Outliers – To Remove, Or Not To Remove?

It has been sometime since I have set foot in a lab, but the thought of seeing outliers in my data still sends a shiver down my spine –... read more →

22nd February 2021
All Blogs, Bioassay

What is a Simulated Treatment Comparison, and can it help my HTA submission?

In this blog we will describe an alternative approach to indirect comparison - Simulated Treatment Comparison (STC) and discuss the key aspects to consider when looking to use the... read more →

12th November 2020
All Blogs, HTA

Failing Goodness-of-Fit: How to Combat the F-test Headache

We have all experienced the frustration (and sometimes utter dejection!) of performing a bioassay to what you thought was near perfection only to come back, analyse the data, and... read more →

3rd November 2020
All Blogs, Bioassay

Sample Size and Other Common Medical Device Trial Design Errors that Matter

Designing and running a clinical trial for a medical device is expensive, and to avoid wasting money, time and risking the validity of the trial, it is important to get... read more →

28th October 2020
All Blogs, Devices

Hidden Consequences of Interim Analyses & Adaptive Trial Options

Interim analyses are common in medical device trials for a variety of reasons. Just having a look is fine, but if the outcome of the analysis could change the conduct... read more →

20th August 2020
All Blogs, Devices

Unanchored comparison between the single arm trials A and C and between B and C

Matching Adjusted Indirect Comparison (MAIC) – 4 Practical steps to follow

When comparing trial outcomes using standard network meta-analysis (NMA), the assumption is that populations in different trials do not differ in any characteristics that may impact the treatment effect... read more →

29th June 2020
All Blogs, HTA

Vaccine Development: Correlates of Protection Explained

Correlates of protection in determining vaccine efficacy is a topic of particular interest, given the current COVID-19 climate and the spotlight on vaccine development. Here at Quantics, we have... read more →

3rd June 2020
All Blogs, Bioassay

A Review of Statistical Hypothesis Testing

A clinical trial is often designed to demonstrate that a new treatment is performing better than the currently available treatment. To do this, one must show that there is... read more →

22nd May 2020
All Blogs, Clinical, Uncategorised

Bioassay Simulation: Reduce Lab Work

Bioassay simulation can be used during assay development maintenance to supplement and complement the information gained from lab experiments. Bioassay simulation assumes that the available real data is a... read more →

22nd April 2020
All Blogs, Bioassay

Post Covid 19 – Handling Missing Data in Clinical Trials

COVID-19 disruption of clinical trials is likely to result in missing data, disrupted timelines, and perhaps patient population changes. We thought we would dedicate a blog post to the... read more →

14th April 2020
All Blogs, Clinical

Pseudo-replicates and Bioassay

Here, we investigate the difference between true replicates and pseudo-replicates, and discusses the problems that may arise if this difference is ignored or misunderstood in bioassay statistical analysis. Quality... read more →

31st January 2020
All Blogs, Bioassay

pseudo-replicates: Pure Error Bioassay 8 doses

When is Pure Error for Bioassay an Error?

Software systems for calculating relative potencies and other bioanalytical results often provide a choice of variance estimation method, usually: Residuals, Lack of fit Error and Pure Error. This defines... read more →

6th September 2019
All Blogs, Bioassay

The Bursa – Yellowlees Method for Interpolation 5

ELISA Analysis: The Bursa-Yellowlees Method

Interpolation analysis is used to find the concentration of a substance in a sample. For biologics, this is often used in ELISA and other bioanalytic analyses. This blog introduces... read more →

7th June 2019
All Blogs, Bioassay, Uncategorised

Population Adjustment in Network Meta-analysis

In an ideal world, a single randomized controlled trial (RCT) would be used to compare and evaluate the individual treatment effects for all possible treatments of interest. Of course, this... read more →

13th March 2019
All Blogs, HTA, Uncategorised

How to Set Suitability Criteria for Relative Potency Bioassays

We previously discussed the purpose of system suitability tests and sample suitability tests and gave some examples of each. However, we did not explain how to actually set the limits... read more →

15th February 2019
All Blogs, Bioassay

Possible outcomes of a NI Clinical Trial

What is a Non-inferiority Clinical Trial?

In this blog we will discuss a particular type of clinical trial design, the non-inferiority trial. We will explain the difference between non-inferiority trials and more typical clinical trial... read more →

22nd October 2018
All Blogs, Clinical

Suitability Tests for Bioassay

Suitability tests for bioassay are often confusing. In this blog, we discuss the two types of suitability tests: System suitability tests and Sample suitability tests. The blog is deliberately... read more →

31st August 2018
All Blogs, Bioassay

ISS & ISE: Integrated Summary of Safety and Integrated Summary of Effectiveness

What do ISS & ISE mean? ISS & ISE stand for integrated summary of safety and integrated summary of effectiveness, respectively. These are not merely summaries, as the... read more →

20th July 2018
All Blogs, Clinical, Uncategorised

Extrapolating Clinical Trial Data Using Survival Analysis

In our previous blog on survival analysis, we touched on some of the characteristics of survival data and various fundamental methods for analysing such data, focusing solely on non-parametric methods... read more →

14th May 2018
All Blogs, Clinical

Survival analysis for LD50 and vaccine challenge assays

LD50 assays and challenge assays both measure the time to an event, often death, for each animal. However the standard statistical approach to the analysis of the data treats... read more →

19th March 2018
All Blogs, Bioassay

How to Combine Relative Potencies for Bioassay

It often happens that the precision required from a relative potency (RP) bioassay cannot be achieved using a single plate. In this situation the usual approach is to repeat... read more →

20th February 2018
All Blogs, Bioassay

Bootstrap method in dose-response modelling

In a previous blog, we looked at fitting dose-response models to quantal data in ecotoxicology scenarios. To recap, quantal data refers to data where the response variable takes a binary... read more →

10th November 2017
All Blogs, Ecotox

Survival Analysis for Clinical Trials

We have discussed Handling Missing Data in Clinical Trials elsewhere, and mentioned a kind of missing data known as ‘censoring’. In this blog we focus on techniques for dealing... read more →

9th November 2017
All Blogs, Clinical

Software for Bayesian Network Meta-Analyses

In this post we examine the statistical software available for conducting Bayesian network meta-analyses (NMA). The first two sections provide some background information and a review of the available... read more →

13th September 2017
All Blogs, HTA

Response transformation: homogeneity of variance

Response Transformation: When and How?

Our clients sometimes tell us that they don’t want to use response transformations since it feels like an unwarranted manipulation of the data. However, there is little point in... read more →

29th August 2017
All Blogs, Bioassay

Non-parallelism and Biosimilars

Many of our readers will be familiar with our paper “Parallelism in Practice” (PDA Journal of Pharmaceutical Science and Technology, 2015) and how we examined the common methods... read more →

26th July 2017
All Blogs, Bioassay

Planning a Network Meta-analysis

Most network meta-analyses will consist of six key stages - developing the protocol, performing the systematic review, conducting the feasibility assessment, preparing the statistical analysis plan, running the analyses and... read more →

19th July 2017
All Blogs, HTA

Clinical Trial Study populations venn diagram

Study Populations: Clinical Trial Design

The aim of a clinical trial is to make a calculated judgement about the likely clinical effectiveness results that would be seen if the treatments tested were to be... read more →

21st April 2017
All Blogs, Clinical

Complications of fitting 4PL and 5PL models to bioassay data

We have previously discussed the 4 parameter logistic (4PL) model. Sometimes you may see slightly different versions of the 4PL equation – these are all mathematically equivalent. However,... read more →

4th April 2017
All Blogs, Bioassay

The Jonckheere-Terpstra test for ordered differences

Recently our team at Quantics were working on an analysis for an ecotoxicology client which called for us to use the Jonckheere-Terpstra test for ordered differences which is recommended... read more →

4th April 2017
All Blogs, Ecotox

continuouse clinical trial design endpoint

Clinical trial design – Comparing clinical trial endpoint summaries

This 3rd clinical trial design blog from Quantics Biostatistics takes an introductory look at how the various types of clinical endpoints (which we introduced in our previous blog) determine... read more →

24th January 2017
All Blogs, Clinical

Reducing bioassay parallelism failures through better LOQ methodologies

Our recent paper, Estimation of Relative Potency from Bioassay Data that Include Values below the Limit of Quantitation (Francis Bursa, Kelly J. Fleetwood, Karie J. Hirst and Ann Yellowlees), discusses values... read more →

25th October 2016
All Blogs, Bioassay

Improving confidence limits for concentration-response models with quantal data

In ecotoxicology statistics there are three main types of data: continuous discrete quantal / binary Continuous data is that which can take a (numerical) value over a continuous range (e.g.... read more →

11th October 2016
All Blogs, Ecotox

Endpoints: Clinical Trial Design

In our last blog we discussed sample size choice and identified the key information that your statistician needs to know and why. In our second clinical trial design blog we shall... read more →

14th September 2016
All Blogs, Clinical

Choosing a statistical model: Continuous response data

Previously, we discussed the definition of relative potency and how it relates to the concepts of biological similarity, and thus the need for parallelism between the reference dose response... read more →

24th August 2016
All Blogs, Bioassay

The key assumptions of network meta-analysis

Like all statistical analyses, network meta-analysis relies on a specific set of assumptions. Here, we’ll look at the key assumptions of network meta-analysis. In order to draw valid conclusions... read more →

29th July 2016
All Blogs, HTA

Ecotoxicology – NOEC and LOEC

Ecotoxicity tests are experiments performed to evaluate the toxicity of a test substance in order to predict the effect on natural populations. There are many different types of test,... read more →

12th July 2016
All Blogs, Ecotox

What is Relative Potency?

Relative potency (RP) refers to the dose of a test sample required to produce the same response in an assay as a dose of a reference sample. Since we... read more →

4th July 2016
All Blogs, Bioassay

How to Inform Sample Size Calculations for Clinical Trials

Welcome to Quantics' Clinical blog. This blog will explore some of the statistical aspects of clinical trial design including study design, sample size, data management and analysis planning. The aims... read more →

29th June 2016
All Blogs, Clinical

An introduction to network meta-analysis (mixed treatment comparison / indirect treatment comparison)

Find out about our network meta analysis services Welcome to Quantics' health technology assessment blog. This blog will explore some of the statistical aspects of health technology assessment, including... read more →

29th June 2016
All Blogs, HTA

Discussions and insights

on statistical issues in life sciences

Be First In Line